FILING ANALYSIS · WEDNESDAY, OCTOBER 28
DBV Technologies S.A. DBVT — 8-K: Results of Operations and Financial Condition
neutral
DBV Technologies has submitted a Biologics License Application to the FDA for the VIASKIN Peanut Patch in children aged 4-7 years and requested Priority Review, with a potential launch in the US if approved, and has $165.7 million in cash and cash equivalents, funding into third quarter of 2027. However, the company also refreshed its $150 million ATM program and completed a $50 million sale of AD
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →